Qynapse - Quantitative imaging and beyond

USING AI AND NEUROIMAGING

ADVANCED CLINICAL TRIALS AND THERAPIES

OPTIMIZED THERAPIES

OPTIMAL MEASURES

NEWS

QYNAPSE to Present at Sachs 4th Annual Neuroscience Innovation Forum

April 26, 2021

QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.

Qynapse joins Decentralized Trials & Research Alliance (DTRA) to democratize and accelerate clinical trials

December 30, 2020

QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

QYNAPSE to sponsor and exhibit at the 106th RSNA Annual Meeting and present its latest AI-neuroimaging advancements, which are transforming care for patients with brain disorders

November 24, 2020

QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.

QYNAPSE appoints Matt Ullum as Chief Commercial Officer to drive and accelerate its growth globally

November 12, 2020

QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

OUR CLIENTS

PHARMAS

A solution for supporting the data-driven selection of patients, monitoring drug performance and assessing the clinical trials outcomes.

Learn more

HEALTHCARE PROVIDERS

A solution that offers early and extensive insights to assist in personalizing therapies for improved patient care.